BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31707827)

  • 1. Dobutamine Stress Echocardiography Ischemia as a Predictor of the Placebo-Controlled Efficacy of Percutaneous Coronary Intervention in Stable Coronary Artery Disease: The Stress Echocardiography-Stratified Analysis of ORBITA.
    Al-Lamee RK; Shun-Shin MJ; Howard JP; Nowbar AN; Rajkumar C; Thompson D; Sen S; Nijjer S; Petraco R; Davies J; Keeble T; Tang K; Malik I; Bual N; Cook C; Ahmad Y; Seligman H; Sharp ASP; Gerber R; Talwar S; Assomull R; Cole G; Keenan NG; Kanaganayagam G; Sehmi J; Wensel R; Harrell FE; Mayet J; Thom S; Davies JE; Francis DP
    Circulation; 2019 Dec; 140(24):1971-1980. PubMed ID: 31707827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease.
    Al-Lamee R; Howard JP; Shun-Shin MJ; Thompson D; Dehbi HM; Sen S; Nijjer S; Petraco R; Davies J; Keeble T; Tang K; Malik IS; Cook C; Ahmad Y; Sharp ASP; Gerber R; Baker C; Kaprielian R; Talwar S; Assomull R; Cole G; Keenan NG; Kanaganayagam G; Sehmi J; Wensel R; Harrell FE; Mayet J; Thom SA; Davies JE; Francis DP
    Circulation; 2018 Oct; 138(17):1780-1792. PubMed ID: 29789302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptoms as a Predictor of the Placebo-Controlled Efficacy of PCI in Stable Coronary Artery Disease.
    Simader FA; Rajkumar CA; Foley MJ; Ahmed-Jushuf F; Chotai S; Bual N; Khokhar A; Gohar A; Lampadakis I; Ganesananthan S; Pathimagaraj RH; Nowbar A; Davies JR; Keeble TR; O'Kane PD; Haworth P; Routledge H; Kotecha T; Spratt JC; Williams R; Nijjer SS; Sen S; Curzen N; Sinha M; Howard JP; Cole G; Harrell FE; Francis DP; Shun-Shin MJ; Al-Lamee RK;
    J Am Coll Cardiol; 2024 Jul; 84(1):13-24. PubMed ID: 38759906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiopulmonary exercise testing and efficacy of percutaneous coronary intervention: a substudy of the ORBITA trial.
    Ganesananthan S; Rajkumar CA; Foley M; Thompson D; Nowbar AN; Seligman H; Petraco R; Sen S; Nijjer S; Thom SA; Wensel R; Davies J; Francis D; Shun-Shin M; Howard J; Al-Lamee R
    Eur Heart J; 2022 Sep; 43(33):3132-3145. PubMed ID: 35639660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.
    Al-Lamee R; Thompson D; Dehbi HM; Sen S; Tang K; Davies J; Keeble T; Mielewczik M; Kaprielian R; Malik IS; Nijjer SS; Petraco R; Cook C; Ahmad Y; Howard J; Baker C; Sharp A; Gerber R; Talwar S; Assomull R; Mayet J; Wensel R; Collier D; Shun-Shin M; Thom SA; Davies JE; Francis DP;
    Lancet; 2018 Jan; 391(10115):31-40. PubMed ID: 29103656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of Life Assessment in Trials of Revascularization for Chronic Stable Angina: Insights from ORBITA and the Implications of Blinding.
    Nowbar AN; Francis DP; Al-Lamee RK
    Cardiovasc Drugs Ther; 2022 Oct; 36(5):1011-1018. PubMed ID: 34417901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of percutaneous coronary intervention for single-vessel coronary artery disease: an economic evaluation of the ORBITA trial.
    McCreanor V; Nowbar A; Rajkumar C; Barnett AG; Francis D; Graves N; Boden WE; Weintraub WS; Al-Lamee R; Parsonage WA
    BMJ Open; 2021 Feb; 11(2):e044054. PubMed ID: 33563623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind randomised placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina without antianginal medications: design and rationale of the ORBITA-2 trial.
    Nowbar AN; Rajkumar C; Foley M; Ahmed-Jushuf F; Howard JP; Seligman H; Petraco R; Sen S; Nijjer SS; Shun-Shin MJ; Keeble TR; Sohaib A; Collier D; McVeigh P; Harrell FE; Francis DP; Al-Lamee RK
    EuroIntervention; 2022 Apr; 17(18):1490-1497. PubMed ID: 35156616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation).
    Zhang Z; Jones P; Weintraub WS; Mancini GBJ; Sedlis S; Maron DJ; Teo K; Hartigan P; Kostuk W; Berman D; Boden WE; Spertus JA
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e003971. PubMed ID: 29752388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial.
    Foley MJ; Rajkumar CA; Ahmed-Jushuf F; Simader FA; Chotai S; Pathimagaraj RH; Mohsin M; Salih A; Wang D; Dixit P; Davies JR; Keeble TR; Cosgrove C; Spratt JC; O'Kane PD; De Silva R; Hill JM; Nijjer SS; Sen S; Petraco R; Mikhail GW; Khamis R; Kotecha T; Harrell FE; Kellman P; Francis DP; Howard JP; Cole GD; Shun-Shin MJ; Al-Lamee RK
    Lancet; 2024 Apr; 403(10436):1543-1553. PubMed ID: 38604209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina.
    Rajkumar CA; Foley MJ; Ahmed-Jushuf F; Nowbar AN; Simader FA; Davies JR; O'Kane PD; Haworth P; Routledge H; Kotecha T; Gamma R; Clesham G; Williams R; Din J; Nijjer SS; Curzen N; Ruparelia N; Sinha M; Dungu JN; Ganesananthan S; Khamis R; Mughal L; Kinnaird T; Petraco R; Spratt JC; Sen S; Sehmi J; Collier DJ; Sohaib A; Keeble TR; Cole GD; Howard JP; Francis DP; Shun-Shin MJ; Al-Lamee RK;
    N Engl J Med; 2023 Dec; 389(25):2319-2330. PubMed ID: 38015442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inorganic Nitrate in Angina Study: A Randomized Double-Blind Placebo-Controlled Trial.
    Schwarz K; Singh S; Parasuraman SK; Rudd A; Shepstone L; Feelisch M; Minnion M; Ahmad S; Madhani M; Horowitz J; Dawson DK; Frenneaux MP
    J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28887315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II, sham-controlled, double-blinded study testing the safety and efficacy of the coronary sinus reducer in patients with refractory angina: study protocol for a randomized controlled trial.
    Jolicœur EM; Banai S; Henry TD; Schwartz M; Doucet S; White CJ; Edelman E; Verheye S
    Trials; 2013 Feb; 14():46. PubMed ID: 23413981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achieving Optimal Medical Therapy: Insights From the ORBITA Trial.
    Foley M; Rajkumar CA; Shun-Shin M; Ganesananthan S; Seligman H; Howard J; Nowbar AN; Keeble TR; Davies JR; Tang KH; Gerber R; O'Kane P; Sharp ASP; Petraco R; Malik IS; Nijjer S; Sen S; Francis DP; Al-Lamee R
    J Am Heart Assoc; 2021 Feb; 10(3):e017381. PubMed ID: 33496201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dobutamine-induced ST-segment elevation associated with a biphasic response of wall motion in patients with a recent myocardial infarction is caused by myocardial ischaemia and is abolished by revascularization of the infarct-related artery.
    Lanzarini L; Scelsi L; Canosi U; Klersy C; Sebastiani R; Previtali M
    Acta Cardiol; 2003 Dec; 58(6):527-33. PubMed ID: 14713178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, randomised, placebo-controlled trial of the coronary sinus Reducer in refractory angina: design and rationale of the ORBITA-COSMIC trial.
    Foley MJ; Rajkumar CA; Ahmed-Jushuf F; Simader F; Pathimagaraj RH; Nijjer S; Sen S; Petraco R; Clesham G; Johnson T; Harrell FE; Kellman P; Francis D; Shun-Shin M; Howard J; Cole GD; Al-Lamee R
    EuroIntervention; 2024 Feb; 20(3):e216-e223. PubMed ID: 38214677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of cardiac shock wave therapy in patients with stable angina: The design of randomized, triple blind, sham-procedure controlled study.
    Shkolnik E; Burneikaite G; Celutkiene J; Scherbak M; Zuoziene G; Petrauskiene B; Trush E; Laucevicius A; Vasyuk Y
    Anatol J Cardiol; 2018 Feb; 19(2):100-109. PubMed ID: 29424731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
    Bhatt DL; Steg PG; Mehta SR; Leiter LA; Simon T; Fox K; Held C; Andersson M; Himmelmann A; Ridderstråle W; Chen J; Song Y; Diaz R; Goto S; James SK; Ray KK; Parkhomenko AN; Kosiborod MN; McGuire DK; Harrington RA;
    Lancet; 2019 Sep; 394(10204):1169-1180. PubMed ID: 31484629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-of-1 Trial of Angina Verification Before Percutaneous Coronary Intervention.
    Rajkumar CA; Foley MJ; Ahmed-Jushuf F; Simader FA; Mohsin M; Ganesananthan S; Nowbar AN; Chotai S; Sen S; Petraco R; Nijjer SS; Sehmi J; Ruparelia N; Dungu JN; Kabir A; Tang K; Gamma R; Davies JR; Kotecha T; Cole GD; Howard JP; Keeble TR; Clesham G; O'Kane PD; Harrell FE; Francis DP; Shun-Shin MJ; Al-Lamee RK
    J Am Coll Cardiol; 2024 Jul; 84(1):1-12. PubMed ID: 38752902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trimetazidine to reverse ischemia in patients with class I or II angina: a randomized, double-blind, placebo-controlled dobutamine-atropine stress echocardiography study.
    Cesar LA; Mathias W; Armaganijan D; Gimenez V; Jallad S; Del Monaco MI; Bicudo L; Meneguin S; Gomes EP; Brasil CK; Ramires JF
    Coron Artery Dis; 2007 Jun; 18(4):259-63. PubMed ID: 17496489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.